Inhibition of the BCR-Abl Tyrosine Kinase as a Therapeutic Strategy for CML

Oncogene- United Kingdom

doi 10.1038/sj.onc.1206081

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

BCR-ABL Tyrosine Kinase

Science-Business eXchange
2012English

Multidomain Targeting of BCR-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2013English

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

Haematologica
Hematology
2015English

Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor

PLoS ONE
Multidisciplinary
2015English

Inhibition of BCR Serine Kinase by Tyrosine Phosphorylation.

Molecular and Cellular Biology
Cell BiologyMolecular Biology
1996English

Combined Inhibition of MDM2 and BCR-Abl Tyrosine Kinase Targets Chronic Myeloid Leukemia Stem/Progenitor Cells in a Murine Model

Haematologica
Hematology
2019English

A Multiple Reaction Monitoring (MRM) Method to Detect BCR-Abl Kinase Activity in CML Using a Peptide Biosensor

PLoS ONE
Multidisciplinary
2013English

Protein Kinase CKIIa Interacts With the BCR Moiety of BCR/Abl and Mediates Proliferation of BCR/Abl-Expressing Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy